Acorda Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Acorda Therapeutics' es Ron Cohen , nombrado en Jan 1995, tiene una permanencia de 29.42 años. compensación anual total es $996.33K, compuesta por 62.7% salario y 37.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.6% de las acciones de la empresa, por valor de $2.06K. La antigüedad media del equipo directivo y de la junta directiva es de 6.1 años y 21 años, respectivamente.
Información clave
Ron Cohen
Chief Executive Officer (CEO)
US$996.3k
Compensación total
| Porcentaje del salario del CEO | 62.7% |
| Permanencia del CEO | 29.4yrs |
| Participación del CEO | 0.6% |
| Permanencia media de la dirección | 6.1yrs |
| Promedio de permanencia en la Junta Directiva | 21yrs |
Actualizaciones recientes de la dirección
Recent updates
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?
Feb 21
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement
Dec 18Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?
Jun 05Acorda wins $16.5M in Ampyra arbitration case with Alkermes
Oct 17Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote
Oct 10Acorda inks license deal with Asieris for pre-clinical drug
Aug 29Acorda Therapeutics announces resignation of COO
Aug 19Acorda Therapeutics: Managing The Transition
Oct 04Acorda Therapeutics Continues To Maneuver For A Turnaround
Jul 24CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action
Jun 17Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now
May 26Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts
Mar 09Acorda Therapeutics to sell Inbrija manufacturing operations for $80M, reduces headcount by 16%, shares up 65%
Jan 13What Kind Of Investors Own Most Of Acorda Therapeutics, Inc. (NASDAQ:ACOR)?
Jan 04Acorda Therapeutics completes 1-for-6 reverse stock split
Dec 31Acorda Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 05Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$263m |
| Dec 31 2023 | US$996k | US$625k | -US$253m |
| Sep 30 2023 | n/a | n/a | -US$16m |
| Jun 30 2023 | n/a | n/a | -US$21m |
| Mar 31 2023 | n/a | n/a | -US$58m |
| Dec 31 2022 | US$984k | US$625k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$119m |
| Mar 31 2022 | n/a | n/a | -US$95m |
| Dec 31 2021 | US$2m | US$743k | -US$104m |
| Sep 30 2021 | n/a | n/a | -US$166m |
| Jun 30 2021 | n/a | n/a | -US$132m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$2m | US$796k | -US$100m |
| Sep 30 2020 | n/a | n/a | US$49m |
| Jun 30 2020 | n/a | n/a | -US$222m |
| Mar 31 2020 | n/a | n/a | -US$232m |
| Dec 31 2019 | US$2m | US$796k | -US$273m |
| Sep 30 2019 | n/a | n/a | -US$329m |
| Jun 30 2019 | n/a | n/a | -US$79m |
| Mar 31 2019 | n/a | n/a | -US$6m |
| Dec 31 2018 | US$2m | US$796k | US$34m |
| Sep 30 2018 | n/a | n/a | -US$147m |
| Jun 30 2018 | n/a | n/a | -US$158m |
| Mar 31 2018 | n/a | n/a | -US$213m |
| Dec 31 2017 | US$2m | US$792k | -US$223m |
Compensación vs. Mercado: La compensación total de Ron($USD996.33K) está por encima de la media de empresas de tamaño similar en el mercado US ($USD678.50K).
Compensación vs. Ingresos: La compensación de Ron ha aumentado mientras la empresa no es rentable.
CEO
Ron Cohen (68 yo)
29.4yrs
Permanencia
US$996,328
Compensación
Dr. Ron Cohen, M.D., serves as an Independent Director of ZWI Therapeutics, Inc. since January 2024. He has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 29.4yrs | US$996.33k | 0.60% $ 2.0k | |
| CFO & Treasurer | 2.6yrs | US$611.55k | 0% $ 0 | |
| General Counsel & Corporate Secretary | 2.6yrs | US$661.57k | 0% $ 0 | |
| Executive Vice President of Human Resources | 9.4yrs | sin datos | sin datos | |
| Chief Commercial Officer | 2.8yrs | US$592.23k | 0.041% $ 132.3 | |
| Senior VP of Operations & Strategic Planning | no data | sin datos | sin datos | |
| Senior VP of Drug Development & Regulatory Affairs | no data | sin datos | sin datos | |
| Special Scientific Advisor | no data | US$10.00k | sin datos |
6.1yrs
Permanencia media
64yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ACOR.Q es experimentado (6.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 29.4yrs | US$996.33k | 0.60% $ 2.0k | |
| Independent Director | 2.4yrs | US$94.71k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 26.4yrs | US$82.65k | 0.0019% $ 6.3 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-Executive Chairman | 15.5yrs | US$140.22k | 0% $ 0 |
21.0yrs
Permanencia media
70yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de ACOR.Q son experimentados ( 21 años antigüedad media).